LGM2605 Nrf2 Pathway Modulation for Steroid-Resistant Asthma
Solution Overview
Problem
Current treatments for asthma, ozone-induced damage, radiation exposure, and lung cancer lack effective, non-toxic, and affordable options, particularly for steroid-resistant asthma and ozone-induced inflammation, and existing chemopreventive agents are either toxic or ineffective in reducing oxidative stress and airway hyperreactivity.
Innovation Solution
Chemically synthesized secoisolaricirecinol diglucoside (SDG) and its analogs are administered to treat asthma, prevent ozone-induced damage, and protect against radiation and carcinogen exposure, acting through anti-oxidative pathways and immune system modulation independent of glucocorticoid receptors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If glucocorticoids are used to treat severe asthma and airway inflammation, then anti-inflammatory effects are achieved, but they are ineffective in steroid-resistant patients and have toxicity concerns
Solution Approach 1:
The patent changes the mechanism of action parameter from glucocorticoid receptor-dependent to Nrf2 pathway-dependent. LGM2605 acts through oxidative stress reduction and Nrf2 activation, representing a fundamental parameter change in the therapeutic approach, thereby overcoming steroid resistance while maintaining anti-inflammatory effectiveness
Solution Approach 2:
The patent substitutes the glucocorticoid receptor mechanism with an alternative biochemical pathway involving Nrf2 activation and oxidative stress reduction. This mechanism substitution provides efficacy in patients who resist traditional glucocorticoid therapy
2Reliability
If conventional chemopreventive agents are used to reduce oxidative stress and airway hyperreactivity, then some protective effects are achieved, but they are either toxic or ineffective
Solution Approach 1:
The patent changes the chemical structure parameter from conventional chemopreventive agents to secoisolariciresinol diglucoside (SDG) and its analogs. This structural parameter change confers both effectiveness in reducing oxidative stress and airway hyperreactivity, and non-toxicity, simultaneously resolving the contradiction
Solution Approach 2:
The patent converts the harmful effect of oxidative stress into a beneficial therapeutic target. By activating the Nrf2 pathway and enhancing endogenous antioxidant defenses, the compound transforms the body's response to oxidative stress from harmful to protective, achieving chemoprevention without toxicity
3Productivity
If ozone exposure is used to study pulmonary inflammation and airway hyperreactivity, then a relevant asthma model is created, but it causes significant lung damage and inflammation
Solution Approach 1:
The patent applies LGM2605 treatment before or during ozone exposure to prevent lung damage while allowing the ozone-induced inflammation model to proceed. This preliminary protective action preserves research model validity by maintaining the inflammatory response necessary for studying asthma mechanisms, while preventing excessive lung damage
Solution Approach 2:
The patent introduces LGM2605 as an intermediary substance that mediates between ozone exposure and lung tissue. This intermediary protects lung cells from ozone-induced damage through Nrf2 activation and antioxidant mechanisms, while allowing the inflammatory model to remain valid for research purposes
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
SDG effectively reduces airway inflammation, oxidative stress, and hyperreactivity, providing radioprotection and chemoprevention without toxicity, making it a promising treatment for asthma and lung cancer prevention.
Implementation Method 1
LGM2605 is a non-toxic, synthetic lignan secoisolariciresinol diglucoside shown to have robust anti-inflammatory effects independent of the glucocorticoid receptor. Indeed, this novel compound is thought to act via anti-oxidative induction of nuclear factor-E2 related factor 2 (Nrf2) expression, free radical scavenging
Implementation Method 2
this novel compound is thought to act via anti-oxidative induction of nuclear factor-E2 related factor 2 (Nrf2) expression, free radical scavenging, inhibition of myeloperoxidase activity, and impaired NLRP3 inflammasome and NF-κB activation. Expression of Nrf2 in the lung reduced oxidative stress and maintains the proper Th1/Th2 balance
Data Source
AI summary
The invention provides compositions and methods for treating asthma in a subject in need thereof comprising administering chemically synthesized secoisolaricirecinol diglucoside (SDG), and in particular, a racemic mixture of the SDG (LGM2605), stereoisomers thereof, metabolites thereof, and analogs thereof. Also provided are methods for treating or preventing ozone-induced damage in a subject in need thereof.



